FBB Biomed Collaborates with Verici Dx for Advanced Testing
FBB Biomed, based in Coralville, Iowa, has signed a strategic Master Services Agreement with Verici Dx plc, specializing in RNA sequencing and laboratory services. This partnership aims to provide clinicians with advanced Research-Use-Only (RUO) tests for neurologic diseases. These tests offer new insights into neurological conditions such as Parkinson’s, Alzheimer’s, Multiple Sclerosis, ALS, Depression, Schizophrenia, and long COVID.
Innovative RUO Tests: A New Hope for Neurological Disorders
The RUO tests developed through this collaboration are cutting-edge and designed to explore the underlying causes of complex neurologic disorders. As the prevalence of neurologic diseases continues to grow globally—intensified by the challenges presented by long COVID—FBB Biomed and Verici Dx are determined to equip medical professionals with crucial research data to enhance patient treatment and outcomes.
Addressing the Need for Better Diagnostics
This partnership signifies an important advancement in the fight against chronic neurological diseases, making RUO tests accessible to healthcare providers committed to improving patient lives. FBB Biomed, with the support and expertise of Verici Dx, is focused on fostering innovation in this critical area of health research.
Insights from Key Leadership
Dr. Howard Urnovitz, CEO of FBB Biomed, expressed enthusiasm regarding the collaboration, stating, “Working alongside Verici Dx, a prominent figure in RNA sequencing, marks a transformative phase for our company. We are now transitioning from a research and development focus to commercial operations, focusing on advancing diagnostics for neurological disorders.”
A Sneak Peek into Future Developments
During an upcoming webinar hosted by LGC Biosearch Technologies, Dr. Urnovitz will share insights from the first 300 samples of the RUO tests, scheduled for early December. This presentation will shed light on how these innovative tools are elevating the standards of neurologic disease research and will provide preliminary information about new diagnostic capabilities poised to benefit researchers and clinicians.
About FBB Biomed
FBB Biomed is a Delaware-based company dedicated to developing advanced diagnostic tests. Their innovative blood-based test serves as an alternative to traditional spinal taps, offering results in less than two weeks—significantly faster than the conventional two years. The company's research is particularly crucial in evaluating the effectiveness of this testing method for conditions related to the COVID-19 pandemic, such as Long COVID.
Frequently Asked Questions
What is the main focus of the partnership between FBB Biomed and Verici Dx?
The partnership aims to provide advanced RUO tests for various neurological disorders, enhancing diagnostic capabilities for clinicians.
How do the RUO tests function?
The RUO tests are designed to help explore and illuminate potential root causes of complex neurological conditions, offering improved diagnostic insights.
What is the significance of these tests for clinicians?
These tests supply vital research data that may assist clinicians in improving treatment and patient outcomes for chronic neurologic diseases.
What does FBB Biomed plan to present in December?
Dr. Urnovitz will present findings from initial test samples during a webinar, highlighting advancements in neurologic disease research.
Where is FBB Biomed located?
FBB Biomed is headquartered in Coralville, Iowa, and operates as a privately held company.
